Passage Bio, Inc.
Passage Bio, Inc. (PASG) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PASG · as of Jun 10, 2026
Key Statistics
Explore Passage Bio, Inc. Data
pasg stock data · financialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 54.5%
The PASG analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +78.57% upside from the current price of $5.60.
Competitors & Peers
pasg competitorsPASG
ALLR
CASI
CING
CLGN
ENLVAbout Passage Bio, Inc.
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to tre…
what is passage bio, inc. · pasg stock overview · passage bio, inc. company profile · who is passage bio, inc. ceo · pasg NASDAQ · passage bio, inc. headquarters · passage bio, inc. business segments
About Stock Overview & Key Data
Passage Bio, Inc. (PASG) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 28, 2020. As of the latest trading session, PASG stock price is $5.60, with a market capitalization of $18.0M. The stock has returned — over the past 12 months and — year-to-date.
Frequently Asked Questions
As of the latest trading session, Passage Bio, Inc. (PASG) stock price is $5.60. The stock is traded on NASDAQ under the ticker symbol PASG. The 52-week range is $3.94 – $20.00.